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Abstract
Introduction: This study was aimed at characterizing basal and adrenocorticotropic hormone (ACTH)-induced
steroidogenesis in sepsis and nonsepsis patients with a suspicion of critical illness-related corticosteroid
insufficiency (CIRCI), taking the use of etomidate-inhibiting 11b-hydroxylase into account.
Method: This was a prospective study in a mixed surgical/medical intensive care unit (ICU) of a university hospital.
The patients were 62 critically ill patients with a clinical suspicion of CIRCI. The patients underwent a 250-μg ACTH
test (n = 67). ACTH, adrenal steroids, substrates, and precursors (modified tandem mass spectrometry) also were
measured. Clinical characteristics including use of etomidate to facilitate intubation (n = 14 within 72 hours of
ACTH testing) were recorded.
Results: At the time of ACTH testing, patients had septic (n = 43) or nonseptic critical illness (n = 24). Baseline
cortisol directly related to sepsis and endogenous ACTH, independent of etomidate use. Etomidate was associated
with a lower baseline cortisol and cortisol/11b-deoxycortisol ratio as well as higher 11b-deoxycortisol, reflecting
greater 11b-hydroxylase inhibition in nonsepsis than in sepsis. Cortisol increases < 250 mM in exogenous ACTH
were associated with relatively low baseline (HDL-) cholesterol, and high endogenous ACTH with low cortisol/ACTH
ratio, independent of etomidate. Although cortisol increases with exogenous ACTH, levels were lower in sepsis
than in nonsepsis patients, and etomidate was associated with diminished increases in cortisol with exogenous
ACTH, so that its use increased, albeit nonsignificantly, low cortisol increases to exogenous ACTH from 38% to 57%,
in both conditions.
Conclusions: A single dose of etomidate may attenuate stimulated more than basal cortisol synthesis. However, it
may only partly contribute, particularly in the stressed sepsis patient, to the adrenal dysfunction of CIRCI, in
addition to substrate deficiency.
Introduction
Activation of the hypothalamic-pituitary-adrenal (HPA)
axis serves to adapt the organism to stress during critical
illness, which may be differently regulated in sepsis and
nonsepsis [1-7]. Particularly in septic shock, elevated
levels of cortisol may be too low for the high level of
stress, as compared with those in nonseptic critical ill-
ness. This may be associated with a diminished adrenal
responsiveness to additional stress, reflected by a dimin-
ished cortisol response to exogenous adrenocorticotropic
hormone (ACTH) [2,5,6]. Adrenal dysfunction may
thereby, together with tissue cortisol resistance, contri-
bute to critical illness-related corticosteroid insufficiency
(CIRCI) and subsequent attributable morbidity and mor-
tality. The diagnosis of CIRCI and treatment with moder-
ate doses of hydrocortisone, particularly in septic shock,
remain highly controversial [2,5,6,8-11]. Mechanisms of
adrenal dysfunction, particularly in the course of sepsis
and shock, may include impaired availability or cleaving
of the substrate (HDL-)cholesterol and impaired activity
of steroidogenic enzymes, limiting an adequate adrenal
stress (ACTH) response [2,6,12-15] (see Figure 1).
Impairment of cortisol secretion at baseline or with exo-
genous ACTH may also develop when (even a single
dose of) etomidate, a known inhibitor of 11b-hydroxylase
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promoting conversion of 11b-deoxycortisol to cortisol, is
used to facilitate intubation [2,4,6,16-29]. Indeed, cortisol
precursors such as 11b-deoxycortisol and its ratio to cor-
tisol have been studied to characterize steroidogenesis
and thereby, occasionally, the role of etomidate and
resultant 11b-hydroxylase inhibition in the adrenal dys-
function of CIRCI [16-20,23].
Hyperreninemic hypoaldosteronism also may develop
in the critically ill [16,18,30,31]. This may contribute to
hypotension and underlie the rationale for treatment of
CIRCI with fludrocortisone, because inhibition of 11b-
hydroxylase increases levels of 11b-deoxycorticosterone
by inhibiting conversion to corticosterone and from
there to aldosterone [2,16,18-20,30,31]. Hence, the adre-
nal dysfunction of CIRCI either may directly result from
etomidate use [7,23,27,29,32], or etomidate may be only
a risk factor [2,4,9,20-22,25,28]. The importance of prior
etomidate for adrenal dysfunction, depending on under-
lying disease, and its harmful sequelae thus remain
highly controversial [4,5,9,16,20-26,28,29,32,33]. During
the adrenal dysfunction of CIRCI, impaired cortisol
synthesis may also occur upstream of the final 11b-
hydroxylase steps, thereby potentially attenuating an
increase in 11b-deoxycortisol but not in circulating
ACTH via feedback, as during 11b-hydroxylase inhibi-
tion [3,18]. Decreased 21-hydroxylase activity, increasing
progesterone and 17-OH-progesterone, is a potential
mechanism [20]. Decreased 3-hydroxysteroid dehydro-
genase activity would result in decreased progesterone
and 17-OH-progesterone and increased dehydroepian-
drosterone(-sulfate) (DHEA(S)) relative to androstene-
dione levels, even though DHEA may be increased and
DHEAS decreased in critical illness [34,35].
We analyzed adrenal steroidogenesis separately in sep-
sis and nonsepsis critically ill patients with suspected
CIRCI, intubated with or without administration of eto-
midate, in response to endogenous or exogenous ACTH
and on the basis of circulating hormones and precur-
sors. The aim was to characterize adrenal dysfunction
with the hypothesis that use of etomidate has a major
impact on its occurrence and assessment.
Materials and methods
Patient population and study design
This prospective observational study was carried out in a
mixed surgical/medical intensive care unit (ICU) of a uni-
versity hospital from December 2004 to March 2007.
Dutch legislation waives the need for informed consent as
the ACTH test is routinely performed in the unit for clini-
cal reasons, no extra blood is drawn for this study on pre-
cursors, and the provided results are treated anonymously.
We included critically ill patients older than 18 years,
admitted to the ICU, and being suspected of CIRCI. Suspi-
cion of CIRCI was based on > 6 hours hypotension (< 100
mm Hg systolic) requiring repeated fluid challenges and/or
vasopressor/inotropic treatment in the ICU. Patients were
excluded if they had a history of HPA axis disease and if
they had taken glucocorticosteroids in the preceding
24 hours. Patients were otherwise treated by attending
intensivists in rotating shifts, in this 30-bed unit, admitting
about 1,500 patients annually. Patients were admitted either
after surgery or from medical wards. In our hospital, etomi-
date is used to facilitate intubation in the operating/recov-
ery room or ICU, at a dose of 0.2 to 0.4 mg/kg; propofol
(1 to 1.5 mg/kg) and/or midazolam (5 to 15 mg) are used





























Figure 1 Schematic presentation of steroidogenesis. 3BHSD, 3-hydroxysteroid-dehydrogenase; CYP11B1, 11ß-hydroxylase; CYP11B2, 11 and
18-hydroxylase; CYP17, 17-hydroxylase and 17,20-hydroxylase; CYP21, 21-hydroxylase.
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Data collection
On the day of the ACTH test, the following parameters
were recorded: time from ICU admission, age and sex,
common clinical conditions at admission according to the
international classification of disease-10 definitions and
severity of illness, as assessed by the APACHE II score.
Sepsis was defined as the presence of systemic inflamma-
tory response syndrome (SIRS) with a clinical source of
infection and a positive microbiologic local (urine, trachea,
or other) and/or blood culture. SIRS was defined as two or
more of the following criteria: a temperature > 38°C or
< 36°C, a leukocyte count > 12 or < 4 × 109/L, a heart rate
> 90 beats per minute, and a respiratory rate > 20 breaths
per minute, or arterial PCO2 < 32 mm Hg or the presence
of mechanical ventilation. For laboratory measurements,
blood was sampled before and 30 and 60 minutes after
intravenous injection of 250 μg of synthetic ACTH
(Synacthen). Blood was sampled in heparinized syringes,
centrifuged at 3,000 rpm, and plasma was stored at
-80°C until assayed. A low cortisol increase to ACTH
was defined according to a cutoff level of 250 nM
[1,2,4,5,7-9,11,14,23,33]. Interventions including type and
doses of vasopressor/inotropics, use of etomidate in the
preceding 72 hours, need for mechanical ventilation, and
renal replacement therapy at the time of the ACTH test
were recorded. Administration of phenytoin and flucona-
zole was recorded. After the day of the ACTH test, the
following data were recorded: outcome until day 28 of
ICU or hospital stay, outcome in the ICU, and length of
ICU stay. Five patients (of whom three had sepsis) were
tested more than once, at least 48 hours after discontinua-
tion of hydrocortisone therapy and more than 72 hours
after etomidate use, if any.
Assays
Steroid precursor hormone levels were determined with
help of tandem mass spectrometry (Applied Biosystems Q
trap 3200) slightly modified after the previous description
[36]. Reference values are shown in Table 1. The
procedure was as follows. To 1 ml of sample, standard or
quality control sample 150 μl of internal standard (corti-
sol-d4 and 17a-hydroxyprogesterone-d8) solution was
added and deproteinized with 3 ml acetonitrile while vor-
texing. After centrifugation (20 minutes, 18°C, 3,000 rpm),
the supernatant was evaporated at 58°C under a constant
flow of nitrogen. The components were resolved in 1 ml
methanol-water (1:3) by vortexing. The solution was
further purified by solid-phase extraction (SPE) by using
Polarplus Octadecyl C18 columns from JT Baker. The
sample was transferred to the conditioned SPE columns,
washed with 2 ml distilled water (AD), and eluted with
3 ml acetone. The eluent was evaporated, resolved with
100 L methanol-water (1:3), and transferred to high-per-
formance liquid chromatography (HPLC) vials. For the
liquid chromatography-mass spectrometry (LC-MS) mea-
surements, a Shimadzu HPLC system consisting of two
LC-20AD pumps, an SIL-20AC autosampler, a CTO-20A
column oven, and a CBM-20A controller unit was coupled
to a Q-Trap 3200 mass spectrometer from Applied Biosys-
tems. All MS investigations were carried out with an
atmospheric pressure photoionization source, which was
operated in both positive and negative ion modes under
multiple-reaction monitoring (MRM) conditions. Other
laboratory measurements included total cholesterol (n <
6.5 mM) and HDL cholesterol (n > 0.9 mM) determined
with enzymatic colorimetric assay (Modular P analytics;
Roche Diagnostics, Mannheim, Germany). ACTH was
determined with an immunometric assay, and CBG, with
radioimmunoassay (Immulite 2500; Siemens Medical
Diagnostic Solutions, Deerfield, IL, USA, and BioSource,
Nivelles, Belgium; n 30-54 mg/L). Cortisol was determined
with competitive immunoassay (Centaur; Siemens Medical
Diagnostic Solutions) as described before [5,9,11].
Statistical analysis
The Fisher Exact test was used for categoric variables,
and the Mann-Whitney U test, for continuous variables,
because most data were distributed nonnormally (Kol-
mogorov-Smirnov test, P < 0.05). Generalized estimating
equations (GEEs) were performed, taking repeated mea-
surements in the same patients into account, to evaluate
the effect of the underlying condition, use of etomidate,
and their first-order interaction, after logarithmic trans-
formation to normalize distributions. For correlations,
the Pearson linear r was used. A two-sided P < 0.05 is
considered to indicate statistical significance, and exact




Table 2 shows patient characteristics on admission
according to etomidate treatment. Twenty-one percent
Table 1 Reference hormone values for adults
ACTH < 9 pM
Progesterone (nonluteal phase) < 5 nM
Corticosterone < 30.0 nM
Aldosterone < 5.0 nM
17-OH-progesterone < 15.0 nM
11b-deoxycortisol < 11.0 nM
Cortisol 150-600 nM
DHEA < 60 years 1.0-25.0 μM
≥ 60 years 0.5-8.0 μM
DHEAS 2.0-17.0 nM
Androstenedione 2.0-15.0 nM
ACTH, adrenocorticotropic hormone; DHEA(S), dehydroepiandrosterone
(sulfate).
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of patients had received etomidate for intubation within
72 hours before blood sampling and an ACTH test. No
group differences were found, except for more-frequent
respiratory failure as a reason for admission in the eto-
midate group. Mortality was unaffected by etomidate.
Of note, most patients had received hydrocortisone.
Etomidate in sepsis and nonsepsis
Table 3 shows characteristics according to underlying
condition and etomidate use. Although all patients were
initially intubated and mechanically ventilated, some of
them had been extubated before the ACTH test, and
the time from admission to the test was shorter in eto-
midate than in non-etomidate intubated patients. The
patients with sepsis had a lower MAP and higher nore-
pinephrine dose at the time of the ACTH test. Etomi-
date was associated with a lower MAP, particularly in
nonsepsis, and higher norepinephrine requirements.
Table 4 shows metabolic and hormonal values. Baseline
cholesterol was lower in sepsis than in nonsepsis and
when etomidate was used, whereas cortisol was higher in
the former. The baseline 11b-deoxycortisol was elevated,
and cortisol and cortisol/11b-deoxycortisol were
depressed, particularly in nonsepsis, when etomidate was
used. Endogenous ACTH did not differ among groups.
Etomidate attenuated the increase of cortisol to exogenous
ACTH in sepsis and nonsepsis alike, whereas the increase
was lower in the former. Figure 2 shows that the ACTH
test response did not correlate to the baseline cortisol/
11b-deoxycortisol ratio in both sepsis and nonsepsis
patients and whether or not etomidate was used. Indeed,
the frequency of a low cortisol increase (< 250 nM) was
not significantly affected by etomidate: for sepsis and non-
sepsis together, a low cortisol increase occurred in 57% of
ACTH tests preceded by etomidate and in 38% not pre-
ceded by etomidate. Six patients had etomidate with a
baseline 11b-deoxycortisol > 8 nM and an increase in cor-
tisol on ACTH < 250 nM (defining etomidate-induced
adrenal dysfunction, 22), of whom four had sepsis, and
three died. Finally, etomidate increased 17-OH-progester-
one and decreased aldosterone relative to corticosterone,
particularly in the nonsepsis group. The drug increased
DHEAS and androstenedione, irrespective of the underly-
ing condition.
Adrenal dysfunction of CIRCI
Table 5 shows that cortisol increases < 250 mM were asso-
ciated with low baseline cholesterol, largely independent of
etomidate. Baseline ACTH was relatively high (and the
cortisol/ACTH ratio low) when the increase in cortisol on
exogenous ACTH was low. Etomidate decreased endogen-
ous ACTH and increased cortisol/ACTH, particularly in
the group normally responding to exogenous ACTH. Eto-
midate increased baseline 11b-deoxycortisol and decreased
cortisol, cortisol/11b-deoxycortisol ratio, and cortisol
increases on exogenous ACTH, whether the latter was low






Age, years 66 (22) 67 (17) 0.36
Sex, m/f 8 (57)/6 (43) 26 (54)/22 (46) 1.0
Admission syndromesa
Trauma and postoperative 4(29) 19 (40) 0.54
Cardiac surgery 2(14) 10 (21) 0.72
Vascular surgery 0 7 (15) 0.33
Respiratory failure 9 (64) 13 (27) 0.02
Post-CPR 1 (7) 9 (19) 0.43
Shock 3 (21) 2 (4) 0.07
Sepsis 4 (29) 15 (31) 1.0
Renal insufficiency 0 4 (8) 0.57
Coma 0 4 (8) 0.57
Other 3 (21) 2 (4) 0.07
Start hydrocortisone after first test
Number 13 (93) 45 (94) 1.0
Duration, days 7 (13) 8 (8) 0.71
Fluconazole/phenytoin 2 (14) 4 (8) 0.62
Length of stay ICU, days 18 (23) 20 (24) 0.60
Mortality day 28 5 (36) 15 (31) 0.75
Mortality ICU 5 (36) 19 (40) 1.0
Data are expressed as median (interquartile range) or number (%), where appropriate; CPR, cardiopulmonary resuscitation; ICU, intensive care unit; na, not
applicable. aPatients may have more than one condition.
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Table 3 Sepsis and nonsepsis on ACTH test day, and etomidate, no etomidate, and other variables before the ACTH
test
Sepsis Nonsepsis P
Etomidate No etomidate Etomidate No etomidate
n = 11 n = 32 n = 3 n = 21 S, E, E*S
Days admission to test 1 (2) 3 (9) 1 (2) 12 (17) 0.11, < 0.001, 0.06
APACHE II 17 (8) 18 (6) 17 (10) 14 (7) 0.29, 0.56, 0.73
Focus sepsis
Respiratory 4 (36) 18 (56) - - na, 0.52, na
Abdominal 4 (36) 6 (19) - -
Genitourinary - 1 (3) - -
Soft tissue 1 (9) 3 (9) - -
Endocarditis 1 (9) - - -
Meningitis - 1 (3) - -
Unknown 1 (9) 3 (9) - -
Bacteria involved na, 0.59, na
Gram+ 2 3 - -
Gram- 3 13 - -
Mixed and others 1 1 - -
Gram- bacteremia 4 - - na, 0.83, na
Gram+ bacteremia 1 3 - -
Mechanical ventilation 11 (100) 28 (88) 3 (100) 15 (71) 1.0, 0.98, 1.0
Renal replacement therapy 2 (18) 9 (28) 1 (33) 1 (5) 0.31, 0.54, 0.13
MAP, mm Hg 76 (17) 73 (17) 70 (14) 91 (21) 0.02, < 0.001, < 0.001
Norepinephrine 11 (100) 22 (69) 2 (67) 9 (43) 0.005, < 0.001, 0.07
Dopamine 0 2 (6) 1 (33) 3 (14) 0.15, 0.66, 0.37
Data are expressed as median (interquartile range) or number (%), where appropriate. APACHE, Acute Physiology, Age and Chronic Health Evaluation; MAP, mean
arterial pressure; S, sepsis; E, etomidate; E*S, interaction between the two in generalized estimating equations; na, not applicable.
Table 4 Metabolic and hormonal measurements on ACTH test day
Sepsis Nonsepsis P
Etomidate No etomidate Etomidate No etomidate
n = 11 n = 32 n = 3 n = 21 S, E, E*S
ACTH, pM 1.4 (3.1) 2.4 (2.6) 1.9 (7.5) 4.1 (3.9) 0.37, 0.10, 0.22
Cholesterol, mM 1.3 (0.8) 1.8 (1.2) 2.4 (1.8) 2.8 (1.0) < 0.001, 0.02, 0.75
HDL-cholesterol, mM 0.40 (0.40) 0.60 (0.60) 0.80 (0.80) 0.90 (0.60) 0.06, 0.18, 0.17
Progesterone, nM 0.40 (0.90) 0.50 (0.70) 1.0 (1.0) 0.60 (0.70) 0.55, 0.34, 0.16
Corticosterone, nM 3.4 (4.9) 3.5 (6.4) 5.3 (4.6) 4.0 (7.4) 0.23, 0.04, 0.64
Aldosterone, nM 1.3 (1.3) 0.70 (1.3) 0.50 (0.1) 1.2 (0.7) 0.08, 0.13, 0.007
17-OH-progesterone, nM 2.9 (2.8) 2.6 (1.5) 3.9 (2.1) 2.5 (2.4) 0.48, 0.09, < 0.001
11ß-deoxycortisol, nM 15 (58) 3.1 (8.3) 34 (30) 3.7 (3.3) 0.003, < 0.001, < 0.001
Cortisol, nM 460 (200) 500 (221) 325 (134) 455 (335) 0.03, 0.98, 0.04
Cortisol/11ß-deoxycortiso l26 (175) 157 (352) 12 (28) 316 (380) 0.04, < 0.001, < 0.001
Cortisol/ACTH 209 (340) 223 (229) 171 (270) 109 (80) 0.07, 0.08, 0.08
Cortisol increase, nM 220 (190) 298 (315) 165 (169) 395 (238) 0.04, < 0.001, 0.98
Cortisol increase < 250 nM 6 (54) 14 (44) 2 (67) 6 (29) 0.92, 0.17, 0.43
DHEA, μM 6.1 (4.6) 6.4 (4.9) 6.1 (1.8) 5.9 (4.1) 0.61, 0.61, 0.44
DHEAS, nM 0.70 (1.4) 0.48 (0.76) 0.50 (4.2) 0.90 (1.1) 0.39, 0.03, 0.87
Androstenedione, nM 3.8 (8.6) 2.4 (2.9) 3.6 (2.8) 2.8 (2.4) 0.13, 0.02, 0.60
Median (interquartile range) or number (%). ACTH, adrenocorticotropic hormone; CBG, cortisol-binding globulin; DHEA(S), dihydroxyepiandrostenedione (sulfate).
S, sepsis; E, etomidate; E*S, interaction between etomidate and sepsis in generalized estimating equations; HDL, high-density lipoprotein.
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or high. Groups otherwise did not differ in 17-OH-proges-
terone, progesterone, corticosterone, aldosterone, DHEA,
and androstenedione levels, whereas etomidate increased
DHEAS levels.
Multivariable models
The time from admission to ACTH test did not contri-
bute to the following models. Baseline cortisol related to
sepsis and the ACTH level (both P = 0.03), whereas the
APACHE II score and use of etomidate did not contri-
bute. The increase in cortisol with exogenous ACTH
inversely related to baseline cortisol/ACTH ratio or
ACTH (P = 0.01) and etomidate (P = 0.05) and directly
to HDL-cholesterol (P = 0.03), but not to sepsis, base-
line cholesterol, and cortisol (to 11b-deoxycortisol ratio).
Discussion
Our study on steroidogenesis suggests that, in critically ill
sepsis patients, the 11b-hydroxylase inhibiting effect of
etomidate did not attenuate a relatively high baseline,
stress-induced cortisol level, dissociated from endogen-
ous ACTH. However, etomidate lowered baseline cortisol
in nonsepsis, and attenuated, in both conditions, the exo-
genous ACTH-induced cortisol increase. Nevertheless,
the effects on ACTH tests were not large enough to con-
found significantly the assessment of the adrenal dysfunc-
tion of CIRCI, as defined before [2,3,5,6,8-11,15,24,32].
Although etomidate thus affects exogenous ACTH-
stimulated more than basal cortisol synthesis, it only par-
tially contributes, on top of substrate deficiency, to the
adrenal dysfunction of CIRCI, particularly in sepsis.
Our data suggest that baseline cortisol increased in par-
allel to endogenous ACTH and was therefore higher in
sepsis than in nonsepsis, independent of etomidate and
low (HDL-)cholesterol levels, which serve as substrates
for steroidogenesis [11,15,23]. A lower cholesterol in eto-
midate versus nonetomidate-intubated patients can be
explained in part by greater acuity of disease [15],
because the time from admission to the ACTH test was
shorter in the former. Otherwise, the tendency for a high
Figure 2 Poor relation between cortisol/11b-deoxycortisol ratio
and delta cortisol. The figure represents the relation between
cortisol/11b-deoxycortisol and the cortisol increase with exogenous
ACTH, in septic (upper panel, r = 0.14; p = 0.77) and nonseptic
(lower panel, r = 0.19; p = 0.38) patients, without (open symbols) or
with (solid symbols) etomidate. For etomidate: r = -0.34; p = 0.23;
for no etomidate, r = -0.07; p = 0.61.
Table 5 Adrenal dysfunction of critical illness-related corticosteroid insufficiency on ACTH test day
Cortisol increase < 250 nM Cortisol increase ≥ 250 nM P
Etomidate No etomidate Etomidate No etomidate C, E, E*C
n = 8 n = 20 n = 6 n = 33
ACTH, pM 2.8 (4.6) 4.0 (11) 1.1 (1.8) 2.5 (2.6) 0.02, 0.001, 0.27
Cholesterol, mM 1.6 (1.5) 1.6 (1.0) 1.4 (0.7) 2.5 (1.0) 0.03, 0.06, 0.07
HDL-cholesterol, mM 0.60 (0.30) 0.40 (0.40) 0.40 (0.50) 0.90 (0.50) 0.09, 0.13, 0.04
Progesterone, nM 0.90 (1.5) 0.70 (0.80) 0.40 (0.70) 0.60 (0.60) 0.63, 0.83, 0.39
Corticosterone, nM 2.6 (3.1) 4.3 (8.0) 6.0 (7.2) 3.3 (6.5) 0.71, 0.71, 0.06
Aldosterone, nM 0.90 (1.2) 0.90 (1.3) 1.5 (1.3) 1.0 (1.3) 0.34, 0.95, 0.90
17-OH-progesterone, nM 3.2 (2.3) 2.5 (2.4) 2.5 (3.2) 2.6 (1.5) 0.10, 0.16, 0.12
11ß-deoxycortisol, nM 25 (56) 2.8 (11) 17 (45) 2.0 (4.9) 0.26, 0.05, 0.50
Cortisol, nM 427 (192) 518 (294) 460 (230) 460 (310) 0.64, 0.70, 0.06
Cortisol/11ß-deoxycortisol 13 (139) 177 (400) 38 (170) 229 (372) 0.15, < 0.001, 0.96
Cortisol/ACTH 180 (120) 107 (154) 395 (376) 165 (227) < 0.001, < 0.001, 0.004
Cortisol increase, nM 121 (114) 180 (118) 280 (30) 440 (163) na, < 0.001, na
DHEA, μM 6.4 (2.6) 6.1 (5.6) 5.5 (4.1) 6.1 (3.9) 0.88, 0.48, 0.80
DHEAS, nM 1.0 (2.5) 0.48 (1.1) 0.55 (0.98) 0.59 (0.90) 0.55, 0.03, 0.16
Androstenedione, nM 3.7 (8.7) 2.9 (3.8) 3.6 (5.6) 2.2 (2.4) 0.23, 0.93, 0.19
Median (interquartile range). ACTH, adrenocorticotropic hormone; C, low cortisol increase; CBG, cortisol-binding globulin; DHEA(S), dihydroxyepiandrostenedione
(sulfate); E, etomidate; E*C, interaction between the two in generalized estimating equations; HDL, high-density lipoprotein; na, not applicable.
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cortisol/ACTH ratio in sepsis might be attributed to non-
ACTH stimulation contributing to the commonly
observed cortisol/ACTH dissociation [2,3,6,7,20]. In any
case, the adrenals were not sensitized to ACTH because
of the lower increase in cortisol with exogenous ACTH
in sepsis than in nonsepsis. Our data suggest a greater
effect of etomidate on baseline cortisol/11b-deoxycortisol
ratio and cortisol in nonsepsis than in sepsis, whereas the
effect on 11b-deoxycortisol and its ratio to cortisol
reflecting 11b-hydroxylase inhibition is in line with the
literature [3,4,7,16-20,22,23,26,27]. The observation that
etomidate barely affected baseline HPA-axis activity,
independent of the time between admission and etomi-
date administration and conversely on blood sampling, is
supported by the lack of increase in endogenous ACTH
with the decrease in the cortisol/11b-deoxycortisol ratio.
Because of decreased endogenous ACTH levels with
prior etomidate both in low and normal increases to exo-
genous ACTH, we cannot, however, exclude a small and
negative effect of etomidate on the pituitary, in contrast
to in vitro observations [17], and possibly caused by seda-
tion and reduction of stress. The limited effect of a single
dose of etomidate on baseline cortisol may relate in part
to the time window chosen, because inhibition is highest
shortly after administration and usually resolves after 48
to 72 hours [8,16,22,23,27-29].
In contrast to relatively spared baseline HPA axis
activity, etomidate-induced inhibition of 11b-hydroxy-
lase, which was greater in nonsepsis than in sepsis, was
associated with a inhibition of the cortisol response to
supraphysiologic doses of exogenous ACTH, regardless
of underlying condition and cortisol-binding molecules
that hardly affect ACTH-induced cortisol increases [11].
Conversely, the higher endogenous ACTH level at < 250
cortisol increases with exogenous ACTH, independent
of etomidate, supports relatively insufficient baseline
and exogenous ACTH-stimulated secretion by the adre-
nals at this cutoff, and the combination thus suggests
adrenal dysfunction in the course of CIRCI, as argued
before [2,3,5,6,8,10,15,24,29,32]. Conversely, the occur-
rence of low cortisol increases was nonsignificantly
increased by etomidate, which inhibited both low and
normal cortisol increases to exogenous ACTH. The
level did not exceed 8 nM in 57% of patients with an
ACTH-induced increase in cortisol < 250 nM, thereby
supporting that etomidate and 11b-hydroxylase inhibi-
tion were not the only factors inhibiting cortisol
increases. Also, the increase in cortisol with exogenous
ACTH being dependent on both prior etomidate and
baseline ACTH in multivariable analysis strongly sup-
ports that a low cortisol increase reflects CIRCI-asso-
ciated adrenal dysfunction, partly independent of
etomidate (Figure 2). This supports direct inhibition of
cortisol synthesis in the adrenals, as demonstrated in
septic conditions, for instance, after a substrate deficit
by low cholesterol levels [2,3,6,12-14,20]. In any case,
lack of evidence of inhibition of 21-hydroxylase (and
3-hydroxysteroid dehydrogenase) activity in adrenal dys-
function concords with a pediatric study on meningo-
coccemia [20].
However, numbers may have been too low for a 19%
increased risk by etomidate of low cortisol increases
with exogenous ACTH to reach statistical significance,
in contrast to what has been described before
[4,10,16,19,22,24,28,32]. In the latter studies, greater
inhibition by etomidate of cortisol increases to exogen-
ous ACTH may have resulted in part from lower stress
and cortisol baseline values and thus greater reserve on
stimulation [29]. Also, effects of etomidate may be dose
dependent, so that greater and more frequent inhibition
of ACTH-induced cortisol increases than observed in
our study may partly relate to higher doses used by
others [16,17,19,24].
Etomidate did not affect circulating levels of other
adrenal hormones, synthesized independent of 11b-
hydroxylase. Etomidate slightly increased corticosterone
relative to aldosterone (in nonsepsis), but our data do not
suggest hypoaldosteronism caused by etomidate, even at
low cortisol increases to ACTH, in contrast to the litera-
ture [16,18,19]. Lower MAP with prior etomidate at the
time of the ACTH test, particularly in nonsepsis patients,
may thus relate, at least in part, to CIRCI rather than to
hyperreninemic hypoaldosteronism after a shift from
mineralo- to glucocorticosteroid production
[16,26,30,31], although an effect of etomidate on MAP
has been refuted [29]. The increase in DHEAS (but not
DHEA), which is usually low in critically ill patients, with
prior etomidate treatment may reflect a shift, by dimin-
ished 11b-hydroxylase, from corticosteroid to androgen
synthesis [14,34,35]. Low DHEAS and androstenedione
levels otherwise support an underlying shift from andro-
gens to corticosteroids during critical illness [26,34,35].
Our relatively small study was not designed to evaluate
the effect of etomidate and replacement doses of hydro-
cortisone on outcome, and was therefore underpowered
to judge those effects. We cannot exclude, however, that
hydrocortisone-replacement therapy had offset a detri-
mental effect of etomidate [5,16,21,23,25,28], although
some literature suggests otherwise [10,32,33]. Unchanged
outcome by etomidate, in line with the literature
[21,24-26], however, did not prompt us to change current
practice and to abandon single doses of the drug, as sug-
gested elsewhere [28,33]. Finally, results should be inter-
preted with caution because the study was not
randomized, even though etomidate and nonetomidate
groups were fairly comparable.
Molenaar et al. Critical Care 2012, 16:R121
http://ccforum.com/content/16/4/R121
Page 7 of 9
Conclusions
Overall, our data suggest that the contribution of a sin-
gle dose of etomidate, inhibiting 11b-hydroxylase up to
72 hours after its administration, on top of substrate
deficiency, in the adrenal dysfunction of CIRCI is lim-
ited, particularly in stressed sepsis patients.
Key messages
• The 11b-hydroxylase inhibiting effect of etomidate
does not attenuate a relatively high baseline cortisol
after stress-induced secretion by the adrenals, so
that the effect on the baseline cortisol/11b-deoxycor-
tisol ratio and cortisol is less in sepsis than in
nonsepsis.
• Etomidate only partially contributes to the adrenal
dysfunction of CIRCI, as assessed with the ACTH
test.
• Our study confirms a primary role for a substrate
deficit and low (HDL-)cholesterol levels in the adre-
nal dysfunction of CIRCI.
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